FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912

No regulatory changes are needed to help firms introduce ingredients that were part of INDs before being removed from consideration as drug ingredients, FDA Assistant Commissioner Ireland tells members of Congress. But FDA still has no answer on introducing ingredients studied in clinical trials but not in INDs.